One-year follow-up study of patients with enterochromaffin-like cell carcinoids after treatment with octreotide long-acting release

Scandinavian Journal of Gastroenterology

Volumn 40, Issue 11, 2005, Pages 1269-1274

  Fykse, Vidar ^b   Sandvik, Arne Kristian ^b   Waldum, Helge Lyder ^a  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NONE

Author keywords

Carcinoid; ECL cell; Follow up; Hypergastrinaemia; Somatostatin analogue

Indexed keywords

CHROMOGRANIN A; ERYTHROSINE; GASTRIN; HEMATOXYLIN; OCTREOTIDE; SOMATOSTATIN DERIVATIVE;

ADULT; AGED; ARTICLE; ATROPHIC GASTRITIS; BILIARY COLIC; CARCINOID; CHOLELITHIASIS; CLINICAL ARTICLE; ENTEROCHROMAFFIN CELL; FEMALE; FOLLOW UP; GASTROINTESTINAL ENDOSCOPY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERGASTRINEMIA; IMMUNOHISTOCHEMISTRY; MALE; PERNICIOUS ANEMIA; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOID TUMOR; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENTEROCHROMAFFIN CELLS; FEMALE; FOLLOW-UP STUDIES; GASTRIC MUCOSA; HUMANS; MALE; OCTREOTIDE; PROSPECTIVE STUDIES; RISK ASSESSMENT; SAMPLING STUDIES; STOMACH NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 27844453890     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520510023684     Document Type: Article

References (33)

1. Havu N, Maaroos HI, Sipponen P. Argyrophil cell hyperplasia associated with chronic corpus gastritis in gastric ulcer disease. Scand J Gastroenterol 1991;Suppl 186:90-4.
2. Solcia E, Capella C, Sessa F, Rindi G, Cornaggia M, Riva C, et al. Gastric carcinoids and related endocrine growths. Digestion 1986;35 Suppl 1:3-22.
3. Ryberg B, Tielemans Y, Axelson J, Carlsson E, Håkanson R, Mattson H, et al. Gastrin stimulates the self-replication rate of enterochromaffinlike cells in the rat stomach. Effects of omeprazole, ranitidine, and gastrin-17 in intact and antrectomized rats. Gastroenterology 1990;99:935-42.
4. Håkanson R, Tielemans Y, Chen D, Andersson K, Mattsson H, Sundler F. Time-dependent changes in enterochromaffin-like cell kinetics in stomach of hypergastrinemic rats. Gastroenterology 1993;105:15-21.
5. Zamcheck N, Grable E, Ley A, Norman L. Occurrence of gastric cancer among patients with pernicious anemia at the Boston City Hospital. N Engl J Med 1955;252:1103-10.
6. Kokkola A, Sjøblom SM, Haapiainen R, Sipponen P, Puolakkainen P, Jarvinen H. The risk of gastric carcinoma and carcinoid tumours in patients with pernicious anaemia. A prospective follow-up study. Scand J Gastroenterol 1998;33:88-92.
7. Borch K, Renvall H, Liedberg G. Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anemia. Gastroenterology 1985;88:638-48.
8. Rindi G, Luinetti O, Cornaggia M, Capella C, Solcia E. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 1993;104:994-1006.
9. Syversen U, Jacobsen MB, O'Connor DT, Ronning K, Waldum HL. Immunoassays for measurement of chromogranin A and pancreastatin-like immunoreactivity in humans: correspondence in patients with neuroendocrine neoplasia. Neuropeptides 1994;26:201-6.
10. Nobels FR, Kwekkeboom DJ, Coopmans W, Schoenmakers CH, Lindemans J, De Herder WW, et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 1997;82:2622-8.
11. Borch K, Stridsberg M, Burman P, Rehfeld JF. Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis. Scand J Gastroenterol 1997;32:198-202.
12. Waldum HL, Syversen U. Chromogranin A (CGA) and the enterochromaffin-like (ECL) cell. Adv Exp Med Biol 2000;482:361-7.
13. Prinz C, Sachs G, Walsh JH, Coy DH, Wu SV. The somatostatin receptor subtype on rat enterochromaffinlike cells. Gastroenterology 1994;107:1067-74.
14. Fykse V, Sandvik AK, Qvigstad G, Falkmer SE, Syversen U, Waldum HL. Treatment of ECL cell carcinoids with octreotide LAR. Scand J Gastroenterol 2004;39:621-8.
15. Kleveland PM, Haugen SE, Waldum HL. The preparation of bioactive 125I-gastrin, using Iodo-gen as oxidizing agent, and the use of this tracer in receptor studies. Scand J Gastroenterol 1985;20:569-76.
16. Syversen U, Ramstad H, Gamme K, Qvigstad G, Falkmer S, Waldum HL. Clinical significance of elevated serum chromogranin A levels. Scand J Gastroenterol 2004;39:969-73.
17. Brenna E, Waldum HL. Trophic effect of gastrin on the enterochromaffin-like cells of the rat stomach: establishment of a dose response relationship. Gut 1992;33:1303-6.
18. Bakke I, Sandvik AK, Waldum HL. Octreotide inhibits the enterochromaffin-like cell but not peroxisome proliferator-induced hypergastrinemia. J Mol Endocrinol 2000;25:109-19.
19. Chanson P, Timsit J, Harris AG. Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. Clin Pharmacokinet 1993;25:375-91.
20. Wahid ST, Marbach P, Stolz B, Miller M, James RA, Ball SG. Partial tachyphylaxis to somatostatin (SST) analogues in a patient with acromegaly: the role of SST receptor desensitisation and circulating antibodies to SST analogues. Eur J Endocrinol 2002;146:295-302.
21. Gillis JC, Noble S, Goa KL. Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly. Drugs 1997;53:681-99.
22. Plockinger U, Dienemann D, Quabbe HJ. Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly. J Clin Endocrinol Metab 1990;71:1658-62.
23. Trendle MC, Moertel CG, Kvols LK. Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors. Cancer 1997;79:830-4.
24. Hussaini SH, Pereira SP, Veysey MJ, Kennedy C, Jenkins P, Murphy GM, et al. Roles of gall bladder emptying and intestinal transit in the pathogenesis of octreotide induced gall bladder stones. Gut 1996;38:775-83.
25. Lembcke B, Creutzfeldt W, Schleser S, Ebert R, Shaw C, Koop I. Effect of the somatostatin analogue sandostatin (SMS 201-995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men. Digestion 1987;36:108-24.
26. Creutzfeldt W, Lembcke B, Folsch UR, Schleser S, Koop I. Effect of somatostatin analogue (SMS 201-995, Sandostatin) on pancreatic secretion in humans. Am J Med 1987;82:49-54.
27. ++ secretion by the gallbladder: a risk factor for gallstones. Surgery 1999;125:509-13.
28. Modlin IM, Lye KD, Kidd M. A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol 2004;99:23-32.
29. Thomas RM, Baybick JH, Elsayed AM, Sobin LH. Gastric carcinoids. An immunohistochemical and clinicopathologic study of 104 patients. Cancer 1994;73:2053-8.
30. Qvigstad G, Falkmer S, Westre B, Waldum HL. Clinical and histopathological tumour progression in ECL cell carcinoids ("ECLomas" ). APMIS 1999;107:1085-92.
31. Rindi G, Azzoni C, La Rosa S, Klersy C, Paolotti D, Rappel S, et al. ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology 1999;116:532-42.
32. Solcia E, Bordi C, Creutzfeldt W, Dayal Y, Dayan AD, Falkmer S, et al. Histopathological classification of nonantral gastric endocrine growths in man. Digestion 1988;41:185-200.
33. Waldum HL, Brenna E, Sandvik AK, Syversen U, Falkmer S. Hormones and carcinogenesis. Endocrine-Related Cancer 1998;5:45-8.